spacer
spacer
Go to PDB code: 
protein ligands metals Protein-protein interface(s) links
Hydrolase PDB id
1mkd
Jmol
Contents
Protein chains
(+ 6 more) 328 a.a. *
Ligands
ZAR ×12
Metals
_ZN ×12
_MG ×12
Waters ×12
* Residue conservation analysis
PDB id:
1mkd
Name: Hydrolase
Title: Crystal structure of pde4d catalytic domain and zardaverine complex
Structure: Phosphodiesterase 4d. Chain: a, b, c, d, e, f, g, h, i, j, k, l. Fragment: catalytic domain. Synonym: camp-specific 3',5'-cyclic phosphodiesterase 4d. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562.
Biol. unit: Hexamer (from PQS)
Resolution:
2.90Å     R-factor:   0.245     R-free:   0.260
Authors: M.E.Lee,J.Markowitz,J.-O.Lee,H.Lee
Key ref:
M.E.Lee et al. (2002). Crystal structure of phosphodiesterase 4D and inhibitor complex(1). FEBS Lett, 530, 53-58. PubMed id: 12387865 DOI: 10.1016/S0014-5793(02)03396-3
Date:
29-Aug-02     Release date:   01-Mar-03    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
Q08499  (PDE4D_HUMAN) -  cAMP-specific 3',5'-cyclic phosphodiesterase 4D
Seq:
Struc:
 
Seq:
Struc:
809 a.a.
328 a.a.*
Key:    PfamA domain  PfamB domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 Enzyme reactions 
   Enzyme class: E.C.3.1.4.17  - 3',5'-cyclic-nucleotide phosphodiesterase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Nucleoside 3',5'-cyclic phosphate + H2O = nucleoside 5'-phosphate
Nucleoside 3',5'-cyclic phosphate
+ H(2)O
= nucleoside 5'-phosphate
Molecule diagrams generated from .mol files obtained from the KEGG ftp site
 Gene Ontology (GO) functional annotation 
  GO annot!
  Biological process     signal transduction   1 term 
  Biochemical function     catalytic activity     2 terms  

 

 
    Added reference    
 
 
DOI no: 10.1016/S0014-5793(02)03396-3 FEBS Lett 530:53-58 (2002)
PubMed id: 12387865  
 
 
Crystal structure of phosphodiesterase 4D and inhibitor complex(1).
M.E.Lee, J.Markowitz, J.O.Lee, H.Lee.
 
  ABSTRACT  
 
Cyclic nucleotide phosphodiesterases (PDEs) regulate physiological processes by degrading intracellular second messengers, adenosine-3',5'-cyclic phosphate or guanosine-3',5'-cyclic phosphate. The first crystal structure of PDE4D catalytic domain and a bound inhibitor, zardaverine, was determined. Zardaverine binds to a highly conserved pocket that includes the catalytic metal binding site. Zardaverine fills only a portion of the active site pocket. More selective PDE4 inhibitors including rolipram, cilomilast and roflumilast have additional functional groups that can utilize the remaining empty space for increased binding energy and selectivity. In the crystal structure, the catalytic domain of PDE4D possesses an extensive dimerization interface containing residues that are highly conserved in PDE1, 3, 4, 8 and 9. Mutations of R358D or D322R among these interface residues prohibit dimerization of the PDE4D catalytic domain in solution.
 
  Selected figure(s)  
 
Figure 2.
Fig. 2. Dialkoxyphenyl containing PDE4 inhibitors [4, 6, 15, 16, 23, 24 and 25]. IC[50] values are written in parentheses. The dialkoxy pharmacophores are colored in red.
Figure 4.
Fig. 4. The dimerization of wild type and mutant PDE4D catalytic domain. A: Purified wild type and R358D mutant protein were injected into a Superdex 200 (APbiotech) gel filtration column. Elution volumes for molecular weight standards are indicated. B: Glutaraldehyde-mediated cross-linking of the purified wild type and mutant proteins was performed as published [26]. The cross-linked proteins were separated by SDS–PAGE and stained with Coomassie brilliant blue R-250. Glutaraldehyde concentrations used for each lanes are, 1, 6, 11: 0%; 2, 7, 12: 0.01%; 3, 8, 13: 0.03%; 4, 9, 14: 0.1%; 5, 10, 15: 0.3%. Mutant catalytic domains of PDE4D were cloned into the pAcHLTA vector (BD Pharmingen) and expressed using a baculovirus expression system. Mutant proteins could not be overexpressed in Escherichia coli. They run in as slightly higher molecular weight due to hexa-histidine tags. In control experiments with wild type protein expressed in insect cells, the histidine tag did not affect cross-linking results (data not shown).
 
  The above figures are reprinted by permission from the Federation of European Biochemical Societies: FEBS Lett (2002, 530, 53-58) copyright 2002.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
21530250 R.W.Allcock, H.Blakli, Z.Jiang, K.A.Johnston, K.M.Morgan, G.M.Rosair, K.Iwase, Y.Kohno, and D.R.Adams (2011).
Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.
  Bioorg Med Chem Lett, 21, 3307-3312.  
21437195 W.C.Ko, L.H.Lin, H.Y.Shen, C.Y.Lai, C.M.Chen, and C.H.Shih (2011).
Biochanin a, a phytoestrogenic isoflavone with selective inhibition of phosphodiesterase 4, suppresses ovalbumin-induced airway hyperresponsiveness.
  Evid Based Complement Alternat Med, 2011, 635058.  
19464886 A.P.Skoumbourdis, C.A.Leclair, E.Stefan, A.G.Turjanski, W.Maguire, S.A.Titus, R.Huang, D.S.Auld, J.Inglese, C.P.Austin, S.W.Michnick, M.Xia, and C.J.Thomas (2009).
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
  Bioorg Med Chem Lett, 19, 3686-3692.  
19828435 J.Pandit, M.D.Forman, K.F.Fennell, K.S.Dillman, and F.S.Menniti (2009).
Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct.
  Proc Natl Acad Sci U S A, 106, 18225-18230.
PDB codes: 3ibj 3itm 3itu
18243697 A.P.Skoumbourdis, R.Huang, N.Southall, W.Leister, V.Guo, M.H.Cho, J.Inglese, M.Nirenberg, C.P.Austin, M.Xia, and C.J.Thomas (2008).
Identification of a potent new chemotype for the selective inhibition of PDE4.
  Bioorg Med Chem Lett, 18, 1297-1303.  
18757755 S.Liu, M.N.Mansour, K.S.Dillman, J.R.Perez, D.E.Danley, P.A.Aeed, S.P.Simons, P.K.Lemotte, and F.S.Menniti (2008).
Structural basis for the catalytic mechanism of human phosphodiesterase 9.
  Proc Natl Acad Sci U S A, 105, 13309-13314.
PDB codes: 3dy8 3dyl 3dyn 3dyq 3dys
17376027 M.Conti, and J.Beavo (2007).
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.
  Annu Rev Biochem, 76, 481-511.  
16102838 C.Lugnier (2006).
Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.
  Pharmacol Ther, 109, 366-398.  
18044094 D.Wang, and X.Cui (2006).
Evaluation of PDE4 inhibition for COPD.
  Int J Chron Obstruct Pulmon Dis, 1, 373-379.  
16735511 H.Wang, Y.Liu, Q.Huai, J.Cai, R.Zoraghi, S.H.Francis, J.D.Corbin, H.Robinson, Z.Xin, G.Lin, and H.Ke (2006).
Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.
  J Biol Chem, 281, 21469-21479.
PDB codes: 2h40 2h42 2h44
16539372 Q.Huai, Y.Sun, H.Wang, D.Macdonald, R.Aspiotis, H.Robinson, Z.Huang, and H.Ke (2006).
Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.
  J Med Chem, 49, 1867-1873.
PDB codes: 2fm0 2fm5
16407275 R.Zoraghi, J.D.Corbin, and S.H.Francis (2006).
Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.
  J Biol Chem, 281, 5553-5558.  
16873361 S.H.Hung, W.Zhang, R.A.Pixley, B.A.Jameson, Y.C.Huang, R.F.Colman, and R.W.Colman (2006).
New insights from the structure-function analysis of the catalytic region of human platelet phosphodiesterase 3A: a role for the unique 44-amino acid insert.
  J Biol Chem, 281, 29236-29244.  
16912214 Y.Xiong, H.T.Lu, Y.Li, G.F.Yang, and C.G.Zhan (2006).
Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.
  Biophys J, 91, 1858-1867.  
15514991 A.Castro, M.J.Jerez, C.Gil, and A.Martinez (2005).
Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
  Med Res Rev, 25, 229-244.  
15670947 A.Tait, A.Luppi, A.Hatzelmann, P.Fossa, and L.Mosti (2005).
Synthesis, biological evaluation and molecular modelling studies on benzothiadiazine derivatives as PDE4 selective inhibitors.
  Bioorg Med Chem, 13, 1393-1402.  
15994308 H.Wang, Y.Liu, Y.Chen, H.Robinson, and H.Ke (2005).
Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.
  J Biol Chem, 280, 30949-30955.
PDB code: 1zkl
16300476 K.Y.Zhang, P.N.Ibrahim, S.Gillette, and G.Bollag (2005).
Phosphodiesterase-4 as a potential drug target.
  Expert Opin Ther Targets, 9, 1283-1305.  
16257373 M.D.Houslay, P.Schafer, and K.Y.Zhang (2005).
Keynote review: phosphodiesterase-4 as a therapeutic target.
  Drug Discov Today, 10, 1503-1519.  
15576036 G.L.Card, B.P.England, Y.Suzuki, D.Fong, B.Powell, B.Lee, C.Luu, M.Tabrizizad, S.Gillette, P.N.Ibrahim, D.R.Artis, G.Bollag, M.V.Milburn, S.H.Kim, J.Schlessinger, and K.Y.Zhang (2004).
Structural basis for the activity of drugs that inhibit phosphodiesterases.
  Structure, 12, 2233-2247.
PDB codes: 1xlx 1xlz 1xm4 1xm6 1xmu 1xmy 1xn0 1xom 1xon 1xoq 1xor 1xos 1xot 1xoz 1xp0
15260978 K.Y.Zhang, G.L.Card, Y.Suzuki, D.R.Artis, D.Fong, S.Gillette, D.Hsieh, J.Neiman, B.L.West, C.Zhang, M.V.Milburn, S.H.Kim, J.Schlessinger, and G.Bollag (2004).
A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.
  Mol Cell, 15, 279-286.
PDB codes: 1t9r 1t9s 1taz 1tb5 1tb7 1tbb 1tbf
15210993 Q.Huai, H.Wang, W.Zhang, R.W.Colman, H.Robinson, and H.Ke (2004).
Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding.
  Proc Natl Acad Sci U S A, 101, 9624-9629.
PDB codes: 1tbm 2hd1
14668322 Q.Huai, Y.Liu, S.H.Francis, J.D.Corbin, and H.Ke (2004).
Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity.
  J Biol Chem, 279, 13095-13101.
PDB codes: 1rko 1rkp 1zkn
14728691 S.Kunz, T.Kloeckner, L.O.Essen, T.Seebeck, and M.Boshart (2004).
TbPDE1, a novel class I phosphodiesterase of Trypanosoma brucei.
  Eur J Biochem, 271, 637-647.  
15131123 W.Richter, and M.Conti (2004).
The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases.
  J Biol Chem, 279, 30338-30348.  
12955149 B.J.Sung, K.Y.Hwang, Y.H.Jeon, J.I.Lee, Y.S.Heo, J.H.Kim, J.Moon, J.M.Yoon, Y.L.Hyun, E.Kim, S.J.Eum, S.Y.Park, J.O.Lee, T.G.Lee, S.Ro, and J.M.Cho (2003).
Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.
  Nature, 425, 98.
PDB codes: 1udt 1udu 1uho
  12842049 Q.Huai, H.Wang, Y.Sun, H.Y.Kim, Y.Liu, and H.Ke (2003).
Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity.
  Structure, 11, 865-873.
PDB codes: 1oym 1oyn 1q9m
14551206 T.Yoshimura, I.Sagami, Y.Sasakura, and T.Shimizu (2003).
Relationships between heme incorporation, tetramer formation, and catalysis of a heme-regulated phosphodiesterase from Escherichia coli: a study of deletion and site-directed mutants.
  J Biol Chem, 278, 53105-53111.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB codes are shown on the right.